0000950170-24-016424.txt : 20240216 0000950170-24-016424.hdr.sgml : 20240216 20240216163012 ACCESSION NUMBER: 0000950170-24-016424 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240214 FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dorval Allison CENTRAL INDEX KEY: 0001625110 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40489 FILM NUMBER: 24648840 MAIL ADDRESS: STREET 1: C/O INSULET CORPORATION STREET 2: 600 TECHNOLOGY PARK DRIVE, SUITE 200 CITY: BILLERICA STATE: MA ZIP: 01821 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Verve Therapeutics, Inc. CENTRAL INDEX KEY: 0001840574 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 824800132 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: (978) 501-3026 MAIL ADDRESS: STREET 1: 201 BROOKLINE AVENUE STREET 2: SUITE 601 CITY: BOSTON STATE: MA ZIP: 02215 4 1 ownership.xml 4 X0508 4 2024-02-14 0001840574 Verve Therapeutics, Inc. VERV 0001625110 Dorval Allison C/O VERVE THERAPEUTICS, INC. 201 BROOKLINE AVENUE, SUITE 601 BOSTON MA 02215 false true false false Chief Financial Officer false Stock Option (right to buy) 12.75 2024-02-14 4 A false 180000 0 A 2034-02-13 Common Stock 180000 180000 D Restricted Stock Units 2024-02-14 4 A false 45000 0 A Common Stock 45000 45000 D The option was granted on February 14, 2024. 25% of the shares underlying the option will vest on February 14, 2025, and the remainder are scheduled to vest in equal monthly installments thereafter until February 14, 2028. Each restricted stock unit represents a contingent right to receive one share of common stock. On February 14, 2024, the reporting person was granted restricted stock units, vesting in four equal annual installments, beginning on April 1, 2025, and the remaining three installments vesting on April 1, 2026, April 1, 2027 and April 1, 2028. /s/ Andrew Ashe, as Attorney-in-Fact for Allison Dorval 2024-02-16